^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

V-FAST master trial: Preliminary results of treatment with CPX-351 plus midostaurin in adults with newly diagnosed FLT3-mutated acute myeloid leukemia.

Published date:
05/26/2022
Excerpt:
A total of 23 patients received CPX-351 + MID and had sufficient data to be included in the analysis ...Preliminary results from the V-FAST trial suggest CPX-351 + MID is feasible, with a manageable safety profile and promising remission rates in adults with newly diagnosed AML who have a FLT3 mutation.
DOI:
10.1200/JCO.2022.40.16_suppl.7043
Trial ID: